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Abstract Venous thrombosis is
common in elective hip surgery, and
prophylactic treatment is used up to
12 hours before or after surgery.
Recent clinical trials suggested that
the timing of initiating prophylaxis
significantly influenced the
antithrombotic effectiveness.
Furthermore, the timing of initiating
antifibrinolytic treatment to reduce
blood loss has been a question of
debate. We studied the time course
of coagulation and fibrinolysis at all
phases during total hip arthroplasty.
Specific markers of thrombosis
(prothrombin fragment F1.2) and of
fibrinolysis (plasmin-antiplasmin
(PAP) and D-Dimer) were examined
in eight female and two male
patients aged 16–62 years. There
was a progressive increase in plas-
ma concentrations of F1.2 during
the operation. From the end of oper-
ation to 4 hours afterwards, there
was no further increase in F1.2.
Levels of D-Dimer did not change
until wound closure, when they
began to increase up to 4 hours
postoperatively, but there were no
changes in PAP during the opera-
tion or during the 4-h postoperative
period. Therefore, surgery for total
hip arthroplasty activates thrombin
generation during operation with
fibrin degradation at a later stage.
These observations harmonize with
the notion that the interval between
surgery and first administration of
antithrombotic treatment is a critical
variable. 
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phylaxis is started 12–24 hours postoperatively to mini-
mize bleeding risk [22–26],and there have also been con-
cerns about spinal hematomas related to the practice of
neuraxial anesthesia and use of LMWH prophylaxis [27,
28]. However, the risk of bleeding associated with pro-
phylaxis for venous thromboembolism (VTE) varies
depending on the type and dose of prophylactic medica-
tion. Because of differences in methods of reporting, the
small size of many studies, and the infrequency of post-
operative bleeding complications, meaningful conclu-
sions cannot be drawn as to whether deferring VTE pro-
phylaxis until after surgery appreciably reduces operative
blood loss or subsequent bleeding.
Introduction
Venous thrombosis is common in high-risk surgical
patients and occurs in 40%–60% of patients undergoing
total hip arthroplasty (THA) in the absence of thrombo-
prophylaxis [1, 2]. Clinical practice regarding initiation
of antithrombotic prophylaxis in surgery differs. In
Europe, it is recognized that deep vein thrombosis origi-
nates perioperatively and that preoperative prophylaxis
may optimize antithrombotic effects [3–7]. Low-molecu-
lar-weight heparin (LMWH) is usually initiated 12 hours
preoperatively [8–21]. In North America, LMWH pro-
In orthopaedic surgery, blood loss can be quite sub-
stantial. To minimize bleeding, fibrinolytic inhibitors like
tranexamic acid have been used in total hip replacement,
and lower blood loss has been reported [29–32]. However,
the timing and administration of tranexamic acid varies in
the different studies, and there seems to be no consensus. 
In light of controversies regarding the timing of throm-
boprophylaxis regimens and the administration of tranex-
amic acid, we investigated the time course of thrombosis
and fibrinolysis during total hip replacement as a major
musculoskeletal operation.
Patients and methods
The study enrolled 8 female and 2 male patients who underwent
primary THA with insertion of an uncemented prosthesis
(Landos stem and Harris Galante cup). The patients were unse-
lected and, except for one who had chronic obstructive pul-
monary disease, they were otherwise healthy. The study was
approved by the regional committee on ethics and was per-
formed in accordance with the ethical standards of the
Declaration of Helsinki; written informed consent was obtained
from all patients. 
Anesthesia was standardized with spinal/epidural injections
at the lumbar level with 5 mg/ml bupivacaine (Marcain; Astra-
Zeneca, Södertälje, Sweden). Postopertively, 2.5 mg/ml bupiva-
caine combined with 0.05 mg/ml fentanyl were used epidurally. 
Thromboprophylaxis was given as subcutaneous injections
of 5000 IU LMWH (dalteparin, Fragmin; Pfizer, New York,
USA) the evening before surgery and thereafter daily. Antibiotic
prophylaxis was given as 2 g cefalotin (Keflin; EuroCept
Pharmaceuticals, Kortenhoef, Holland) intravenously, three
times in one day.
Blood samples were drawn from an arterial cannula at the
following time points: control values before surgery, after sec-
tion of the femoral neck, after reaming of the femoral medullary
cavity, 30 min after reaming, at wound closure and 4 h after sur-
gery. Plasma was separated by centrifugation at 2500g for 20
min at 18° C and stored at -80° C until assayed.
Prothrombin fragment F1.2 was measured in citrated plasma
by ELISA using a commercial kit (Enzygnost F1+2 micro; Dade
Behring, Marburg, Germany). Plasmin/α2-antiplasmin (PAP)
complex was measured in citrated plasma by ELISA using a com-
mercial kit (Enzygnost PAP micro, Dade Behring). D-Dimer was
determined in citrated plasma using a commercial kit (STA-
Liatest D-Di; Diagnostica Stago, Asnières s/Seine, France).
Time-dependent changes were analyzed on Friedman’s non-
parametric test for related samples. When significant differences
were found, the Wilcoxon signed rank test was used. The level of
significance was set at p=0.05.
Results
We studied coagulation and fibrinolysis during THA in 10
patients aged 16–62 years. Patient demographics, comorbid-
ity, duration of surgery, blood loss, autotransfusion of blood
and saline and colloid replacements are given in Table 1.
There was a steady increase in prothrombin fragment
F1.2 during surgery (p=0.023) (Table 2). However, from the
end of surgery to 4 hours postoperatively, there was no sig-
nificant change in F1.2 (p=0.499). D-Dimer concentration
was unchanged until wound closure when there was a signif-
icant increase until 4 hours after surgery (p=0.002). During
the course of surgery and up to 4 hours postoperatively, there
were no significant changes in levels of PAP (p=0.288).
188
Table 1 Clinical and operative characteristics of 10 patients who underwent total hip arthroplasty
Patient Sex Age, Comorbidity Surgery Blood Auto- Saline Colloids, ml
years duration, min loss, ml transfusion, ml transfusion, ml
1 F 39 – 120 1000 300 3200 1000
2 F 38 – 80 600 210 2100 500
3 M 17 – 95 1000 – 1500 500
4 F 62 COPD 125 700 214 2000 500
5 F 38 – 120 400 – 2500 500
6 M 16 – 63 300 – 1100 –
7 F 43 – 96 400 – 1250 500
8 F 61 – 100 1000 242 2000 100
9 F 24 – 95 500 – 2000 500
10 F 48 – 110 600 – 2500 500
COPD, chronic obstructive pulmonary disease
Discussion
In this study, markers of thrombosis and fibrinolysis were
measured during the different phases of THA. We found
that intravascular thrombin formation originated at the
start of surgery, and that activation was at a maximum at
the end of surgery. Thrombin formation is a key regulato-
ry step in surgical hemostasis. The short half-life of active
thrombin precludes direct measurements. However, by
conversion of prothrombin to thrombin, the amino termi-
nal of prothrombin is cleaved to generate the inactive F1.2
fragment which is a sensitive marker of prothrombin acti-
vation and thrombin generation [33]. Our observations
harmonize with the understanding that the risk of throm-
bosis starts perioperatively. 
A previous study [34] reported that the greatest activa-
tion of the clotting cascade was during insertion of the
femoral component. However, this was more pronounced
after insertion of a cemented rather than a noncemented
stem. This may be explaned by the fact that when a
cemented stem is impacted, tissue thromboplastin from
the bone and bone marrow is forced into the circulation;
when cement is not used, there is less release of tissue
thromboplastin. Therefore, we used uncemented THA as a
model for thrombin generation during an orthopaedic
operation. It may be argued that there was a rather great
dispersion of age and a skewed distribution of sexes in our
patients. However, the changes in markers during the
experimental period were not related to age or gender of
the patients (data not shown).
A factor contributing to deep vein thrombosis during
total hip arthroplasty may be femoral vein occlusion dur-
ing surgery [34]. In general, venous occlusion triggers
thrombosis. When the hip and leg are flexed and rotated,
the femoral vein is twisted and kinked, and femoral vein
occlusion then may trigger thrombosis. Although femoral
vein occlusion may be an important component in the gen-
esis of deep vein thrombosis during surgery on the lower
extremities, our data do not suggest that it by itself was
sufficient to activate markers. 
Seconday to thrombin generation, fibrinolysis is acti-
vated by plasminogen activator. Plasmin acts on cross-
linked fibrin to generate d-dimers [35], and through its
activation plasmin binds to with α2-antiplasmin inhibitor
to form the plasmin-antiplasmin complex. We measured
D-Dimer and PAP as indicators of plasmin activity. Si-
gnificant degradation of fibrin was found at wound clo-
sure with further increases up to 4 hours postoperatively.
On the other hand, there was no increase in PAP. These
observations concur with previous findings that fibrinolyt-
ic activity is enhanced intraoperatively with a shutdown
after surgery [36]. The postoperative fibrinolytic shut-
down was ascribed to a temporary increase in t-PA in-
hibitor levels after surgery.
The use of tranexamic acid to reduce bleeding in total
hip replacement surgery has been debated, and the timing
and dosage are controversial [32]. Tranexamic acid acts
by inhibiting the activation of plaminogen to plasmin.
However, we found no significant increases in PAP during
and up to 4 hours after surgery. Our results, then, reflect
that systemic use of tranexamic acid to reduce blood loss
during THA may be questioned.
Changes of markers during high-risk surgery are dif-
ficult to translate into a recommendation of timing for
thromboprophylaxis. However, increased plasma con-
centrations of F1.2 and D-Dimer were found to correlate
with thrombosis [33, 37], and our results support the
view that the interval between surgery and the first
administration of prophylaxis is a critical variable that
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Table 2 Prothrombin fragment F1.2, D-Dimer and plasmin-antiplasmin (PAP) complex during and after total hip replacement surgery.
Time points are (1) before anesthesia, (2) after section of the femoral neck, (3) after reaming of the femoral medullary cavity, (4) 30 min
after reaming, (5) at wound closure, and (6) 4 hours after surgery. Median and interquartile ranges are given
Time point F1.2 (pmol·mL-1) D-dimer (µg·mL-1) PAP (µg·L-1)
1 220 (188–240)* 0.09 (0.06–0.28)‡ 930 (368–1302)
2 280 (233–391)* 0.17 (0.07–0.27)‡ 884 (396–967)
3 395 (228–699)‡ 0.21 (0.13–0.39)‡ 872 (508–113)
4 418 (347–757)‡ 0.51 (0.30–0.99)‡ 812 (419–1141)
5 600 (429–713)‡ 1.70 (1.19–3.00)‡ 815 (494–1471)
6 565 (500–1034)# 3.76 (2.04–7.08)§ 806 (509–1063)
p (ANOVA) 0.023‡ 0.002‡ 0.288
*p=0.021, ‡p=0.012, #p=0.008, §p=0.018 vs. values at time point 1
may influence the occurrence of deep vein thrombosis in
patients undergoing elective hip arthroplasty [38].
Thromboprophylaxis in close proximity to hip arthro-
plasty, either preoperatively or postoperatively, may bal-
ance efficacy and safety to prevent thrombosis on one
hand and bleeding on the other hand. Clinical observa-
tions indicated that LMWH at half the usual high-risk
dose begun in close proximity to THA either preopera-
tively or postoperatively [39, 40] was more effective than
LMWH administered 12 hours preoperatively or 12–18
hours postoperatively [17, 19]. However, administration
less than 2 hours before surgery resulted in increased
major bleeding, while a postoperative regimen of
LMWH 4–6 hours after surgery provided efficacy with-
out significantly increasing bleeding [40]. 
In conclusion, our analysis indicates that activation
of thrombin generation and fibrinolysis starts during sur-
gery of THA. The interval between surgery and first
administration of antithrombotic treatment, then, is a
critical variable in musculoskeletal operations with
pathophysiological evidence for the initiation of antico-
agulation during or immediately after surgery.
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